Hemispherx Biopharma Inc, HEB Securities Stock Fraud

Company:	Hemispherx Biopharma Inc,
Ticker Symbol:	HEB
Class Period:	Feb-18-09 to Oct-30-09
Date Filed:	Nov-11-09
Lead Plaintiff Deadline:	Jan-10-10
Court:	Eastern District of Pennsylvania
Allegations:

Philadelphia, PA: A class action lawsuit has been filed in the United States District Court, Eastern District of Pennsylvania on behalf of purchasers of the securities of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company"), between February 18, 2009 and October 30, 2009, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934.

The Complaint alleges that during the Class Period, defendants misled investors regarding the status of Hemispherx's New Drug Application ("NDA") for Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, defendants failed to disclose that the FDA had requested several reports from the Company before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when the Company belatedly disclosed this information, the price of Hemispherx's securities dropped from $1.45 on the previous trading day to close at $1.13 on November 3, 2009, a drop of more than 20%.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Hemispherx Biopharma Inc, HEB Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Hemispherx Biopharma Inc, securities class action lawsuit. Please fill in our form on the right to submit your complaint for a free evaluation.